CLINICAL TRIALS PROFILE FOR ZIAGEN
✉ Email this page to a colleague
All Clinical Trials for ZIAGEN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00004585 ↗ | A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults | Completed | Glaxo Wellcome | Phase 4 | 1999-10-01 | The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and effective in HIV-infected patients. The drug combination includes a tablet containing lamivudine and zidovudine (called Combivir) plus abacavir plus efavirenz. |
NCT00004981 ↗ | Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir) | Unknown status | Glaxo Wellcome | Phase 3 | 1969-12-31 | The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir. |
NCT00005017 ↗ | Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment | Unknown status | Glaxo Wellcome | Phase 4 | 1969-12-31 | The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir (APV)/ritonavir (RTV). |
NCT00038506 ↗ | Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure | Completed | ViiV Healthcare | Phase 4 | 2002-03-01 | This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen. |
NCT00085943 ↗ | KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks | Completed | GlaxoSmithKline | Phase 3 | 2004-05-01 | This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy. |
NCT00102960 ↗ | Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2005-07-01 | The purpose of this study is to compare the effects of anti-HIV drug courses of different lengths in infants who became HIV infected at birth. |
NCT00335192 ↗ | To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir | Completed | Fundacio Lluita Contra la SIDA | Phase 4 | 2005-01-01 | The purpose of this study is to evaluate if there are pharmacokinetic interactions between the NRTI 3TC and ABV, and the TDF nucleotide. For this purpose, the intracellular and plasma levels of 3TC and ABV will be compared in patients given these nucleosides with TDF and 30 days after the interruption of the TDF. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZIAGEN
Condition Name
Clinical Trial Locations for ZIAGEN
Trials by Country
Clinical Trial Progress for ZIAGEN
Clinical Trial Phase
Clinical Trial Sponsors for ZIAGEN
Sponsor Name